T2 BIOSYSTEMS Forum: Community User: Delonghii

@knause ... Danke für den Link

Somit wiederrufe ich meine Aussage von vorhin

Top News! RS abgesagt 🎊🚀

@tvst freue mich wenn deine Kursschätzung mit 3-5$ einigermaßen eintrifft

RS wurde von der Tagesordnung der Jahretagung gestrichen . https://newsfilter.io/articles/t2-biosystems-announces-withdrawal-of-proxy-statement-proposal-to-amend-its-certificate-of-incorpora-5809fc320f616a59b8b1ce282b802025

hier noch der Link! https://insiderfinancial.com/ttoo-stock-huge-move/180055/

Danke👍🏾

*Knau serich

@knauserich. Magst du solche Dinge einfach als Link reinstellen. Dann haben wir alle direkt die Quelle mit dazu. Danke

Vielen Dank für die zahlreichen Informationen. Top👍🏼

SARS-CoV-2 test TTOO stock is currently developing a SARS-CoV-2 test to run on the Company’s proprietary T2Dx Instrument platform and anticipates shipping the first tests to U.S. customers for clinical use as early as the end of this month. The T2SARS-CoV-2 Test is anticipated to be a sample-to-answer test of a nasopharyngeal swab specimen, with a turnaround time of fewer than two hours and a limit of detection of less than 1,000 genomic equivalents per milliliter. Based on significant interest regarding the availability of the T2SARS-CoV-2 Test the Company has received to date, the Company anticipates that there will be demand for the test upon it being made commercially available for clinical use. The Company currently has the resources to manufacture up to 100,000 tests per month and, subject to the success of the Company’s efforts to secure additional non-dilutive funding to support the expansion of manufacturing capacity, estimates that it could potentially ramp to approximately 1,000,000 tests per month. Why The Excitement Around TTOO Stock? TTOO stock is the market leader when it comes to detecting sepsis-causing pathogens. Many deaths from Covid-19 mirror deaths from sepsis, which are also largely preventable with better diagnostic tools. Sepsis, the immune system’s out-of-control response to infection, often leads to organ failure and death. In the US alone, sepsis is responsible for more than 250,000 deaths a year and accounts for 1 in 3 hospital-based deaths. Globally, sepsis kills 6 million people a year and leaves many survivors with lingering physical and mental health issues. Here’s the exciting part. The only FDA cleared system that works directly from blood samples, without upfront culture is the T2Dx from T2 Biosystems, which uses magnetic resonance to deliver results in three to five hours from whole blood samples without isolating the pathogen. A Revenue-Producing Business What differentiates TTOO stock from other small-cap biotech plays is that it is already generating sales. In Q1, TTOO stock reported first-quarter total revenue of $2.5 million and product revenue of $1.0 million, representing an increase of 43% and a decrease of 20% respectively, compared to the prior-year period. The company ended the quarter with $36 million in cash and no debt. Bottom Line TTOO stock was trading above $3 last year when the company was focused solely on sepsis. Now, T2 Biosystems is also focusing on COVID-19 and gearing up to do 1,000,000 tests per month. As a result, we believe the market is mispricing TTOO stock creating a discount entry opportunity. It’s not a question of if a big move is coming in TTOO stock, but when.

Alles klar. Merci. Dann warte ich mit dem Nachlegen definitiv ab

6.8.20 ist fix👍🏾🍀

Hoffentlich liegen die über den Erwartungen und bringen schon Aufwind

Habs auch gerade gelesen. Alles klar. Danke

11.8 stimmt, steht so auch bei Webull